Clinical Trial Update: A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update reporting results from a single ascending-dose study of Daclatasvir (BMS-790052) in chronic hepatitis C patients, covering Phase 1 and P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-09-10